136285-65-9

Usage

Uses

Used in Organic Synthesis:
2-[1.1-dimethyl ethyl ethoxy carbonyl]amino-3-nitro benzoic acid ethyl ester is used as a synthetic intermediate for the preparation of various organic compounds. Its functional groups, such as the nitro group and the amino group, allow for further chemical reactions and modifications, making it a versatile building block in the synthesis of complex molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-[1.1-dimethyl ethyl ethoxy carbonyl]amino-3-nitro benzoic acid ethyl ester is used as a potential precursor for the development of new drugs. Its structural features and reactivity may be harnessed to create novel therapeutic agents with specific biological activities, such as antimicrobial, antiviral, or anticancer properties.
Used in Chemical Research:
2-[1.1-dimethyl ethyl ethoxy carbonyl]amino-3-nitro benzoic acid ethyl ester is used as a research compound in academic and industrial laboratories. Its unique structure and reactivity make it an interesting subject for studies in organic chemistry, potentially leading to new insights into reaction mechanisms, synthetic strategies, and the discovery of new chemical transformations.
Used in Material Science:
In the field of material science, 2-[1.1-dimethyl ethyl ethoxy carbonyl]amino-3-nitro benzoic acid ethyl ester may be used as a component in the development of new materials with specific properties. Its functional groups could be exploited to create novel polymers, coatings, or other materials with tailored characteristics for various applications, such as in electronics, textiles, or biomedical devices.

Upstream product

• 16533-45-2 ethyl 2-carboxy-3-nitrobenzoate 
• 136285-66-0 3-nitro-phthalic acid-1-ethyl ester-2-chloride 
• 75-65-0 tert-butyl alcohol 
• 603-11-2 3-nitrophthalic acid 
• 124341-05-5 2-Azidocarbonyl-3-nitro-benzoic acid ethyl ester 

Downstream Products

• 208772-03-6 ethyl 2-(N-tert-butoxycarbonyl-N-methyl)amino-3-nitrobenzoate 
• 577957-02-9 ethyl 2-ethoxy-3H-benzimidazole-4-carboxylate 
• 167487-83-4 1H-benzoimidazole-7-carboxylic acid ethyl ester 
• 906474-56-4 ethyl 2-[(N-tert-butoxycarbonyl)-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl]biphenyl-4-yl]methyl]amino]-3-nitrobenzoate 
• 1073117-28-8 (+/-)-1-[[(cyclohexyloxy)carbonyl]oxy]ethyl 2-[(N-tert-butoxycarbonyl)-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl]biphenyl-4-yl]methyl]amino]-3-nitrobenzoate 
• 1073117-27-7 2-[(N-tert-butoxycarbonyl)-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl]biphenyl-4-yl]methyl]amino]-3-nitrobenzoic acid 
• 145040-37-5 candesartan cilexetil 
• 61063-11-4 2-Amino-3-nitrobenzoic acid,ethyl ester 

Relevant academic research and scientific papers

Synthesis Method for Candesartan Cilexetil Intermediate

A synthesis method for a candesartan cilexetil intermediate represented by formula (II) is provided. The method includes (1) dissolving a compound represented by formula (IV) to an aprotic solvent to obtain a first mixed solution, and dissolving a phase transfer catalyst and an azidation reagent to water to obtain a second mixed solution; (2) dropping the first mixed solution to the second mixed solution for azidation reaction, and after the reaction is ended, standing and layering same to obtain an organic phase containing a compound represented by formula (V); (3) dropping the obtained organic phase containing the compound represented by formula (V) to tertiary butyl alcohol for rearrangement reaction, and after the reaction is ended, concentrating same to obtain a solid or oily material, then adding a crystallizing solvent to the obtained solid or oily material for recrystallization, and separating same to obtain a crystal.

1-(CYCLOHEXYLOXYCARBONYLOXY)ETHYL 2-ETHOXY-1-[[2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL]METHYL]BENZIMIDAZOLE-7-CARBOXYLATE AND COMPOSITIONS AND METHODS OF PHARMACEUTICAL USE THEREOF

1-(Cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1 H-tetrazol-5-y l)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate or a pharmaceutically acceptable salt thereof has potent angiotensin II antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.

Benzimidazole derivatives and their use

Novel imidazole derivatives of the formula (I): STR1 wherein R1 is an optionally substituted alkyl group, R2 and R3 are independently a group capable of forming an anion or a group which can be changed thereinto, ring A is a benzene ring optionally having, besides the group shown by R2, further substituents, and X shows linkage of phenylene group and phenyl group directly or through a spacer whose atomic length is not more than 2 and a salt thereof, show antagonistic actions to angiotensin II, thus being useful as therapeutics for cardiovascular diseases.